AR103582A1 - Ciclopropabenzofuranil-piridopirazindionas - Google Patents
Ciclopropabenzofuranil-piridopirazindionasInfo
- Publication number
- AR103582A1 AR103582A1 ARP160100286A ARP160100286A AR103582A1 AR 103582 A1 AR103582 A1 AR 103582A1 AR P160100286 A ARP160100286 A AR P160100286A AR P160100286 A ARP160100286 A AR P160100286A AR 103582 A1 AR103582 A1 AR 103582A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- cycloalkyl
- alkyl
- alkoxy
- group
- Prior art date
Links
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 14
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004414 alkyl thio group Chemical group 0.000 abstract 6
- -1 cyano, hydroxy Chemical group 0.000 abstract 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 5
- 150000002431 hydrogen Chemical class 0.000 abstract 5
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- UKQIWANTULDWHD-UHFFFAOYSA-N 7-(4-methylimidazol-1-yl)-2-[[5-(trifluoromethyl)-1,1a-dihydrocyclopropa[b][1]benzofuran-6b-yl]methyl]-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione Chemical compound CC=1N=CN(C=1)C1=CC=C2N(CCN(C2=O)CC23C(OC4=C2C=C(C=C4)C(F)(F)F)C3)C1=O UKQIWANTULDWHD-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000001308 synthesis method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos, composiciones farmacéuticas, métodos de tratamiento, métodos de síntesis, e intermediarios. Reivindicación 1: Un compuesto caracterizado porque tiene la estructura de la fórmula (1), o sales farmacéuticamente aceptables de la misma, en donde: X es un heteroarilo de (5 a 14 miembros) que contiene de 1 - 3 heteroátomos; R¹, cuando se permite químicamente, se selecciona del grupo que consiste de hidrógeno, halógeno, ciano, hidroxi, oxo, -SF₅, nitro, alquilo C₁₋₆ opcionalmente sustituido, alquenilo C₂₋₆ opcionalmente sustituido, alquinilo C₂₋₆ opcionalmente sustituido, alquiltio C₁₋₆ opcionalmente sustituido, alcoxi C₁₋₆ opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, -N(R⁴)(R⁵), -N(R⁴)(C=(O)R⁵), -C(=O)N(R⁴)(R⁵), -O-C(=O)N(R⁴)(R⁵), -C(=O)-R⁴, y -C(=O)-OR⁴; R²ᵃ y R²ᵇ, cuando se permite químicamente, en cada aparición, se seleccionan independientemente del grupo que consiste de hidrógeno, halógeno, ciano, hidroxi, -SF₅, nitro, alquilo C₁₋₆ opcionalmente sustituido, alquenilo C₂₋₆ opcionalmente sustituido, alquinilo C₂₋₆ opcionalmente sustituido, alquiltio C₁₋₆ opcionalmente sustituido, alcoxi C₁₋₆ opcionalmente sustituido, alcoxi C₁₋₆alquilo C₁₋₆ opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, fenilo opcionalmente sustituido, -N(R⁴)(R⁵), -N(R⁴)(C=(O)R⁵), -C(=O)N(R⁴)(R⁵), -O-C(=O)N(R⁴)(R⁵), -C(=O)-R⁴, y -C(=O)-OR⁴; o R²ᵃ y R²ᵇ junto con los átomos de carbono a los cuales se unen, forman un cicloalquilo C₃₋₈ o un heterocicloalquilo de (4 a 10 miembros), en donde el cicloalquilo C₃₋₈ y el heterocicloalquilo de (4 a 10 miembros) se sustituyen opcionalmente con uno a tres R⁸; R⁴ᵃ y R⁴ᵇ, cuando se permite químicamente, se seleccionan cada uno independientemente del grupo que consiste de hidrógeno, halógeno, ciano, hidroxi, oxo, -SF₅, nitro, alquilo C₁₋₆ opcionalmente sustituido, alquenilo C₂₋₆ opcionalmente sustituido, alquinilo C₂₋₆ opcionalmente sustituido, alquiltio C₁₋₆ opcionalmente sustituido, alcoxi C₁₋₆ opcionalmente sustituido, alcoxi C₁₋₆alquilo C₁₋₆ opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, fenilo opcionalmente sustituido, -N(R⁴)(R⁵), -N(R⁴)(C=(O)R⁵), -C(=O)N(R⁴)(R⁵), -O-C(=O)N(R⁴)(R⁵), -C(=O)-R⁴, y -C(=O)-OR⁴; o R⁴ᵃ y R⁴ᵇ junto con el átomo de carbono a los cuales se unen, forman un cicloalquilo C₃₋₈, en donde el cicloalquilo C₃₋₈ se sustituye opcionalmente con uno a tres R⁸; R⁵ᵃ y R⁵ᵇ, en cada aparición, se seleccionan independientemente del grupo que consiste de hidrógeno, halógeno, ciano, hidroxi, oxo, -SF₅, nitro, alquilo C₁₋₆ opcionalmente sustituido, alquenilo C₂₋₆ opcionalmente sustituido, alquinilo C₂₋₆ opcionalmente sustituido, alquiltio C₁₋₆ opcionalmente sustituido, alcoxi C₁₋₆ opcionalmente sustituido, alcoxi C₁₋₆alquilo C₁₋₆ opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, fenilo opcionalmente sustituido, -N(R⁴)(R⁵), -N(R⁴)(C=(O)R⁵), -C(=O)N(R⁴)(R⁵), -O-C(=O)N(R⁴)(R⁵), -C(=O)-R⁴, y -C(=O)-OR⁴; o R⁵ᵃ y R⁵ᵇ junto con el átomo de carbono a los cuales se unen, forman un cicloalquilo C₃₋₈, en donde el cicloalquilo C₃₋₈ se sustituye opcionalmente con uno a tres R⁸; R⁶ y R⁷ se seleccionan cada uno independientemente del grupo que consiste de hidrógeno, halógeno, ciano, -SF₅, nitro, alquilo C₁₋₆ opcionalmente sustituido, alquenilo C₂₋₆ opcionalmente sustituido, alquinilo C₂₋₆ opcionalmente sustituido, alquiltio C₁₋₆ opcionalmente sustituido, alcoxi C₁₋₆ opcionalmente sustituido, alcoxi C₁₋₆alquilo C₁₋₆ opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, fenilo opcionalmente sustituido, -N(R⁴)(R⁵), -N(R⁴)(O=(O)R⁵), -C(=O)N(R⁴)(R⁵), -O-C(=O)N(R⁴)(R⁵), -C(=O)-R⁴, -C(=O)-OR⁴, y -OR⁹; siempre que R⁶ y R⁷ no puedan ser hidroxi; R⁸, en cada aparición, se selecciona independientemente del grupo que consiste de ciano, halógeno, hidroxi, -SF₅, nitro, alquilo C₁₋₆ opcionalmente sustituido, alcoxi C₁₋₆ opcionalmente sustituido, y alcoxi C₁₋₆alquilo C₁₋₆ opcionalmente sustituido; R⁹ se selecciona del grupo que consiste de hidrógeno y alquilo C₁₋₆ opcionalmente sustituido; y es un número entero seleccionado de 1, 2, 3 ó 4; el anillo B se sustituye opcionalmente con uno a tres R¹⁰, en donde cada R¹⁰ se selecciona independientemente del grupo que consiste de halógeno, ciano, hidroxi, -SF₅, nitro, alquilo C₁₋₆ opcionalmente sustituido, alquenilo C₂₋₆ opcionalmente sustituido, alquinilo C₂₋₆ opcionalmente sustituido, alquiltio C₁₋₆ opcionalmente sustituido, alcoxi C₁₋₆ opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, -N(R⁴)(R⁵), N(R⁴)(C=(O)R⁵), -C(=O)N(R⁴)(R⁵), -O-C(=O)N(R⁴)(R⁵), -C(=O)-R⁴, y -C(=O)-OR⁴; o dos sustituyentes R¹⁰ tomados junto con los átomos de carbono a los cuales se unen, forman un cicloalquilo C₃₋₈ opcionalmente sustituido; el anillo D se sustituye opcionalmente con uno a cuatro R¹¹, en donde cada R¹¹ se selecciona independientemente del grupo que consiste de halógeno, ciano, hidroxi, -SF₅, nitro, alquilo C₁₋₆ opcionalmente sustituido, alquenilo C₂₋₆ opcionalmente sustituido, alquinilo C₂₋₆ opcionalmente sustituido, alquiltio C₁₋₆ opcionalmente sustituido, alcoxi C₁₋₆ opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, heterocicloalquilo de (4 a 6 miembros) opcionalmente sustituido; -N(R⁴)(R⁵), -N(R⁴)(C=(O)R⁵), -C(=O)N(R⁴)(R⁵), -O-C(=O)N(R⁴)(R⁵), -C(=O)-R⁴, -C(=O)-OR⁴; y R⁴ y R⁵, en cada aparición, se seleccionan cada uno independientemente de hidrógeno o alquilo C₁₋₆ opcionalmente sustituido; siempre que el compuesto no sea 7-(4-metil-1H-imidazol-1-il)-2-{[5-(trifluorometil)-1,1a-dihidro-6bH-ciclopropa[b][1]benzofuran-6b-il]metil}-3,4-dihidro-2H-pirido[1,2-a]pirazin-1,6-diona.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562111222P | 2015-02-03 | 2015-02-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103582A1 true AR103582A1 (es) | 2017-05-17 |
Family
ID=55299692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100286A AR103582A1 (es) | 2015-02-03 | 2016-02-01 | Ciclopropabenzofuranil-piridopirazindionas |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20160222007A1 (es) |
| EP (1) | EP3253755B1 (es) |
| JP (1) | JP6628805B2 (es) |
| KR (1) | KR102000382B1 (es) |
| CN (1) | CN107406445B (es) |
| AR (1) | AR103582A1 (es) |
| AU (1) | AU2016214102B2 (es) |
| BR (1) | BR112017015693A2 (es) |
| CA (1) | CA2919338A1 (es) |
| DK (1) | DK3253755T3 (es) |
| EA (1) | EA033423B1 (es) |
| EC (1) | ECSP17050310A (es) |
| ES (1) | ES2818806T3 (es) |
| IL (1) | IL253635A0 (es) |
| MX (1) | MX368391B (es) |
| PE (1) | PE20171318A1 (es) |
| PH (1) | PH12017501369A1 (es) |
| SG (1) | SG11201705780PA (es) |
| TN (1) | TN2017000342A1 (es) |
| TW (1) | TWI616445B (es) |
| UY (1) | UY36546A (es) |
| WO (1) | WO2016125048A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102271305B1 (ko) | 2020-05-21 | 2021-06-30 | 주식회사 아리바이오 | 치매 예방 및 치료용 조성물 |
| CN111978324A (zh) * | 2020-08-28 | 2020-11-24 | 开封康诺药业有限公司 | 一种多索茶碱的晶型及其制备方法 |
| KR102272907B1 (ko) | 2020-11-05 | 2021-07-05 | 주식회사 아리바이오 | 치매 예방 및 치료용 조성물 |
| KR102272910B1 (ko) | 2021-01-28 | 2021-07-06 | 주식회사 아리바이오 | 당뇨병을 동반한 치매 예방 및 치료용 조성물 |
| KR102311224B1 (ko) * | 2021-04-23 | 2021-10-13 | 주식회사 아리바이오 | Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물 |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2007107A (en) | 1934-03-07 | 1935-07-02 | Bottrill David Hugh | Combined soap and massage articles |
| GB1419788A (en) | 1972-08-02 | 1975-12-31 | Pfizer | Herbicidal method using 2-trifuluromethyl-4-quinolinols |
| WO1992000075A1 (en) | 1990-06-29 | 1992-01-09 | Pfizer Inc. | Pyridopyrazine derivatives for treating substance abuse and addiction |
| US5482967A (en) | 1992-09-04 | 1996-01-09 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
| US5750349A (en) | 1993-01-25 | 1998-05-12 | Takeda Chemical Industries Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
| DE69628484T2 (de) | 1995-03-24 | 2004-05-19 | Takeda Chemical Industries, Ltd. | Zyklische Verbindungen, ihre Herstellung und ihre Verwendung als Tachykininrezeptorantagonisten |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| ATE402717T1 (de) | 1997-04-09 | 2008-08-15 | Intellect Neurosciences Inc | Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| AU2787299A (en) | 1998-03-03 | 1999-09-20 | Ppg Industries Ohio, Inc. | Impregnated glass fiber strands and products including the same |
| US20020132817A1 (en) | 1998-03-19 | 2002-09-19 | Hideaki Natsugari | Heterocyclic compounds, their production and use |
| EP1145714A4 (en) | 1998-11-27 | 2004-12-15 | Takeda Chemical Industries Ltd | DRUGS |
| SK288711B6 (sk) | 2000-02-24 | 2019-11-05 | Univ Washington | Humanizovaná protilátka, jej fragment a ich použitie, polynukleová kyselina, expresný vektor, bunka a farmaceutický prostriedok |
| DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
| EP1335738A4 (en) | 2000-11-03 | 2004-09-08 | Proteotech Inc | METHODS OF ISOLATING AMYLOID INHIBITOR COMPOUNDS AND USE OF COMPOUNDS USED FROM UNCARIA TOMENTOSA AND PARENT PLANTS |
| WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| CA2498111A1 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
| BR0315158A (pt) | 2002-10-09 | 2005-08-16 | Pfizer Prod Inc | Compostos de pirazol para o tratamento de distúrbios neurodegenarativos |
| BR0315157A (pt) | 2002-10-09 | 2005-08-09 | Rinat Neuroscience Corp | Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste |
| AU2003301439A1 (en) | 2002-10-16 | 2004-05-04 | Gilead Sciences, Inc. | Pre-organized tricyclic integrase inhibitor compounds |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| EP1638935A1 (en) | 2003-06-19 | 2006-03-29 | Pfizer Products Inc. | Nk1 antagonist |
| WO2005020991A1 (en) | 2003-08-21 | 2005-03-10 | Pfizer Products, Inc. | Compounds for the treatment of neurodegenerative disorders |
| CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| US20070155731A1 (en) | 2004-01-28 | 2007-07-05 | Gabor Butora | Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity |
| WO2005080361A1 (en) | 2004-02-02 | 2005-09-01 | Pfizer Products Inc. | Histamine-3 receptor modulators |
| CA2557785A1 (en) | 2004-03-09 | 2005-10-06 | Merck & Co. Inc. | Hiv integrase inhibitors |
| BRPI0509069B8 (pt) | 2004-03-23 | 2021-05-25 | Pfizer Prod Inc | compostos de imidazol e composição farmacêutica que os compreende para o tratamento de distúrbios neurodegenerativos |
| AU2005249363A1 (en) | 2004-04-14 | 2005-12-15 | Zhenhong R. Cai | Phosphonate analogs of HIV integrase inhibitor compounds |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| GEP20115195B (en) | 2004-07-30 | 2011-04-11 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and use thereof |
| GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
| US20090074775A1 (en) | 2004-12-22 | 2009-03-19 | David Michael Holtzman | Use Of Anti-AB Antibody To Treat Traumatic Brain Injury |
| PE20061323A1 (es) | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
| JP4982482B2 (ja) | 2005-05-10 | 2012-07-25 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｈｉｖインテグラ−ゼ阻害剤 |
| WO2006120552A2 (en) | 2005-05-12 | 2006-11-16 | Pfizer Inc. | ANHYDROUS CRYSTALLINE FORMS OF N-[1-(2-ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINO)-7-(4-METHYLPYRIDIN-2-yl-AMINO)-1H-PYRAZOLO[4,3-d]PYRIMIDINE-3-CARBONYL]METHANESULFONAMIDE |
| WO2006126081A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
| CA2608672A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
| WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
| JP2008543923A (ja) | 2005-06-22 | 2008-12-04 | ファイザー・プロダクツ・インク | ヒスタミン−３受容体アンタゴニスト |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| EP1948614A2 (en) | 2005-11-18 | 2008-07-30 | Takeda San Diego, Inc. | Glucokinase activators |
| US20070117839A1 (en) | 2005-11-24 | 2007-05-24 | Eisai R&D Management Co., Ltd. | Two cyclic cinnamide compound |
| JP5221144B2 (ja) | 2005-11-24 | 2013-06-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | モルホリンタイプ・シンナミド化合物 |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| WO2007084595A2 (en) | 2006-01-20 | 2007-07-26 | Schering Corporation | Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| TWI378091B (en) | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
| WO2007105053A2 (en) | 2006-03-13 | 2007-09-20 | Pfizer Products Inc. | Tetralines antagonists of the h-3 receptor |
| BRPI0710658A2 (pt) | 2006-04-21 | 2011-08-16 | Pfizer Prod Inc | compostos de piridina[3,4-b] pirazinonas, seus usos na preparação de composições farmacêuticas e composições farmacêuticas compreendendo os mesmos |
| WO2007136714A2 (en) | 2006-05-16 | 2007-11-29 | Gilead Sciences, Inc. | Integrase inhibitors |
| AU2007252643A1 (en) | 2006-05-19 | 2007-11-29 | Eisai R & D Management Co., Ltd. | Urea type cinnamide derivative |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| SI2124933T1 (sl) | 2007-01-22 | 2012-12-31 | Pfizer Products Inc. | Tosilatna sol terapevtske spojine in farmacevtski sestavi tega |
| CA2676920A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperidine derivatives |
| EP2121633A2 (en) | 2007-02-12 | 2009-11-25 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| US20080207900A1 (en) | 2007-02-28 | 2008-08-28 | Teiji Kimura | Two cyclic oxomorphorin derivatives |
| WO2008137102A2 (en) | 2007-05-04 | 2008-11-13 | Torreypines Therapeutics, Inc. | Methods of modulating amyloid beta and compounds useful therefor |
| JP5209043B2 (ja) | 2007-05-07 | 2013-06-12 | メルク・シャープ・アンド・ドーム・コーポレーション | ガンマセクレターゼ調節剤 |
| ES2358863T3 (es) | 2007-05-11 | 2011-05-16 | F. Hoffmann-La Roche Ag | Hetarilanilinas como moduladores de beta-amiloide. |
| AU2008263206A1 (en) | 2007-06-01 | 2008-12-18 | Schering Corporation | Gamma secretase modulators |
| KR20100037053A (ko) | 2007-06-01 | 2010-04-08 | 쉐링 코포레이션 | 감마 세크레타제 조절인자 |
| EP2166854A4 (en) | 2007-06-13 | 2012-05-16 | Merck Sharp & Dohme | TRIAZOLE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND ASSOCIATED STATES |
| CA2692253A1 (en) | 2007-06-29 | 2009-01-08 | Schering Corporation | Gamma secretase modulators |
| EP2185522A1 (en) | 2007-08-06 | 2010-05-19 | Schering Corporation | Gamma secretase modulators |
| CA2694401C (en) | 2007-08-31 | 2012-12-04 | Eisai R&D Management Co., Ltd. | Polycyclic compound |
| US7935815B2 (en) | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
| WO2009032277A1 (en) | 2007-09-06 | 2009-03-12 | Schering Corporation | Gamma secretase modulators |
| US20100298381A1 (en) | 2007-09-28 | 2010-11-25 | Schering Corporation | Gamma secretase modulators |
| GB0720444D0 (en) | 2007-10-18 | 2007-11-28 | Glaxo Group Ltd | Novel compounds |
| US8487099B2 (en) | 2007-11-05 | 2013-07-16 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| MX2010006244A (es) | 2007-12-06 | 2010-12-02 | Schering Corp | Moduladores de gamma secretasa. |
| CA2708151A1 (en) | 2007-12-11 | 2009-06-18 | Schering Corporation | Gamma secretase modulators |
| MX2010006378A (es) | 2007-12-11 | 2010-09-07 | Schering Corp | Moduladores de gamma secretasa. |
| AU2008335709A1 (en) | 2007-12-13 | 2009-06-18 | Amgen Inc. | Gamma secretase modulators |
| KR101244517B1 (ko) | 2008-01-11 | 2013-03-18 | 에프. 호프만-라 로슈 아게 | 아밀로이드 베타에 대한 조절제 |
| MX2010008700A (es) | 2008-02-22 | 2010-08-30 | Hoffmann La Roche | Moduladores de beta-amiloide. |
| US20100137320A1 (en) | 2008-02-29 | 2010-06-03 | Schering Corporation | Gamma secretase modulators |
| WO2009108766A1 (en) | 2008-02-29 | 2009-09-03 | Schering Corporation | Gamma secretase modulators for the treatment of alzheimer ' s disease |
| CN102083794A (zh) | 2008-05-05 | 2011-06-01 | 安姆根有限公司 | 作为γ分泌酶调节剂的脲化合物 |
| TW201006801A (en) | 2008-07-18 | 2010-02-16 | Lilly Co Eli | Imidazole carboxamides |
| WO2010019393A1 (en) | 2008-08-13 | 2010-02-18 | Merck Sharp & Dohme Corp. | Pyrimidine derivatives for treatment of alzheimer's disease |
| WO2010019392A1 (en) | 2008-08-13 | 2010-02-18 | Merck Sharp & Dohme Corp. | Purine derivatives for treatment of alzheimer's disease |
| EP2324009A1 (en) | 2008-08-27 | 2011-05-25 | Eisai R&D Management Co., Ltd. | Process for preparing certain cinnamide compounds |
| AU2009301210B2 (en) | 2008-10-09 | 2014-05-15 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| JP2012508182A (ja) | 2008-11-06 | 2012-04-05 | シェーリング コーポレイション | γ−セクレターゼ調節剤 |
| CN102272133A (zh) | 2008-11-06 | 2011-12-07 | 阿斯利康(瑞典)有限公司 | 淀粉样β的调节剂 |
| WO2010054064A1 (en) | 2008-11-06 | 2010-05-14 | Schering Corporation | Gamma secretase modulators |
| MX2011004954A (es) | 2008-11-10 | 2011-05-30 | Hoffmann La Roche | Moduladores heterociclicos de gamma-secretasa. |
| WO2010071741A1 (en) | 2008-12-16 | 2010-06-24 | Merck Sharp & Dohme Corp. | Triazole derivatives for treatment of alzheimer's disease |
| US20110313001A1 (en) | 2008-12-16 | 2011-12-22 | Christian Fischer | Triazole derivatives for treatment of alzheimer's disease |
| PA8854101A1 (es) | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa |
| TW201034666A (en) | 2008-12-22 | 2010-10-01 | Schering Corp | Gamma secretase modulators |
| CA2747750A1 (en) | 2008-12-22 | 2010-07-01 | Theodros Asberom | Gamma secretase modulators |
| TW201030002A (en) | 2009-01-16 | 2010-08-16 | Bristol Myers Squibb Co | Bicyclic compounds for the reduction of beta-amyloid production |
| EP2393804B1 (en) | 2009-02-06 | 2014-04-16 | Janssen Pharmaceuticals, Inc. | Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators |
| TWI461425B (zh) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
| JP2012051807A (ja) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | アリールイミダゾール化合物 |
| MX2011006782A (es) | 2009-02-26 | 2011-07-20 | Eisai R&D Man Co Ltd | Sal de derivado de tetrahidrotriazolopiridina y un cristal de la misma. |
| JP2012051805A (ja) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | テトラヒドロトリアゾロピリジン誘導体の製造方法 |
| JP2012051806A (ja) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | イミダゾリルピラジン誘導体 |
| JP2012121809A (ja) | 2009-02-26 | 2012-06-28 | Eisai R & D Management Co Ltd | 多環式化合物の製造法およびその中間体 |
| US20120053165A1 (en) | 2009-03-03 | 2012-03-01 | Pfizer Inc. | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators |
| WO2011048525A1 (en) | 2009-10-20 | 2011-04-28 | Pfizer Inc. | Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators |
| CA2830027C (en) | 2011-03-31 | 2016-04-26 | Pfizer Inc. | Novel bicyclic pyridinones |
| JP6106745B2 (ja) * | 2012-05-16 | 2017-04-05 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | （特に）アルツハイマー病の治療に有用な置換３，４−ジヒドロ−２Ｈ−ピリド［１，２−ａ］ピラジン−１，６−ジオン誘導体 |
| TWI614238B (zh) | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥 |
| UA110688C2 (uk) * | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| CN104918938B (zh) | 2012-12-20 | 2017-08-15 | 詹森药业有限公司 | 新颖的作为γ分泌酶调节剂的三环3，4‑二氢‑2H‑吡啶并[1，2‑a]吡嗪‑1，6‑二酮衍生物 |
| EP2945944B1 (en) | 2013-01-17 | 2016-11-09 | Janssen Pharmaceutica, N.V. | Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators |
| ES2742078T3 (es) | 2013-10-04 | 2020-02-13 | Pfizer | Piridonas bicíclicas novedosas como moduladores de gamma-secretasa |
| CN115068134A (zh) | 2014-03-21 | 2022-09-20 | 阿莱恩技术有限公司 | 具有弹性体的分段的正畸矫正器 |
| ES2759277T3 (es) * | 2014-04-01 | 2020-05-08 | Pfizer | Cromeno y 1,1a,2,7b-tetrahidrociclopropa[c]cromeno piridopiracinadionionas como moduladores de gamma-secretasa |
-
2016
- 2016-01-26 EP EP16702810.9A patent/EP3253755B1/en active Active
- 2016-01-26 JP JP2017540574A patent/JP6628805B2/ja not_active Expired - Fee Related
- 2016-01-26 WO PCT/IB2016/050384 patent/WO2016125048A1/en active Application Filing
- 2016-01-26 ES ES16702810T patent/ES2818806T3/es active Active
- 2016-01-26 SG SG11201705780PA patent/SG11201705780PA/en unknown
- 2016-01-26 TN TNP/2017/000342A patent/TN2017000342A1/en unknown
- 2016-01-26 BR BR112017015693A patent/BR112017015693A2/pt active Search and Examination
- 2016-01-26 KR KR1020177024302A patent/KR102000382B1/ko active IP Right Grant
- 2016-01-26 MX MX2017010019A patent/MX368391B/es active IP Right Grant
- 2016-01-26 EA EA201700356A patent/EA033423B1/ru unknown
- 2016-01-26 PE PE2017001310A patent/PE20171318A1/es not_active Application Discontinuation
- 2016-01-26 AU AU2016214102A patent/AU2016214102B2/en not_active Ceased
- 2016-01-26 DK DK16702810.9T patent/DK3253755T3/da active
- 2016-01-26 CN CN201680008557.7A patent/CN107406445B/zh not_active Expired - Fee Related
- 2016-01-29 CA CA2919338A patent/CA2919338A1/en not_active Abandoned
- 2016-02-01 UY UY0001036546A patent/UY36546A/es not_active Application Discontinuation
- 2016-02-01 TW TW105103193A patent/TWI616445B/zh not_active IP Right Cessation
- 2016-02-01 AR ARP160100286A patent/AR103582A1/es unknown
- 2016-02-02 US US15/012,954 patent/US20160222007A1/en not_active Abandoned
- 2016-12-19 US US15/382,778 patent/US9765073B2/en active Active
-
2017
- 2017-07-24 IL IL253635A patent/IL253635A0/en unknown
- 2017-07-28 PH PH12017501369A patent/PH12017501369A1/en unknown
- 2017-08-03 EC ECIEPI201750310A patent/ECSP17050310A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY36546A (es) | 2016-08-31 |
| BR112017015693A2 (pt) | 2018-03-20 |
| DK3253755T3 (da) | 2020-09-28 |
| JP2018508494A (ja) | 2018-03-29 |
| ECSP17050310A (es) | 2017-11-30 |
| MX368391B (es) | 2019-09-30 |
| WO2016125048A1 (en) | 2016-08-11 |
| CA2919338A1 (en) | 2016-08-03 |
| SG11201705780PA (en) | 2017-08-30 |
| EP3253755B1 (en) | 2020-08-26 |
| CN107406445A (zh) | 2017-11-28 |
| PE20171318A1 (es) | 2017-09-07 |
| US20170096428A1 (en) | 2017-04-06 |
| EA033423B1 (ru) | 2019-10-31 |
| KR102000382B1 (ko) | 2019-07-15 |
| AU2016214102A1 (en) | 2017-07-27 |
| EA201700356A1 (ru) | 2018-01-31 |
| ES2818806T3 (es) | 2021-04-14 |
| CN107406445B (zh) | 2019-12-24 |
| KR20170113603A (ko) | 2017-10-12 |
| EP3253755A1 (en) | 2017-12-13 |
| US9765073B2 (en) | 2017-09-19 |
| IL253635A0 (en) | 2017-09-28 |
| JP6628805B2 (ja) | 2020-01-15 |
| TWI616445B (zh) | 2018-03-01 |
| AU2016214102B2 (en) | 2018-09-27 |
| US20160222007A1 (en) | 2016-08-04 |
| MX2017010019A (es) | 2017-10-24 |
| TN2017000342A1 (en) | 2019-01-16 |
| TW201630913A (zh) | 2016-09-01 |
| PH12017501369A1 (en) | 2017-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR113964A1 (es) | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa | |
| AR118312A2 (es) | Pesticidas de azol bicíclico sustituido con heterociclos | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR103582A1 (es) | Ciclopropabenzofuranil-piridopirazindionas | |
| AR115993A2 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| PE20220567A1 (es) | Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR088449A1 (es) | Benzilindazoles sustituidos | |
| AR103828A1 (es) | INHIBIDORES DEL FACTOR TRANSFORMADOR DEL CRECIMIENTO b | |
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR107042A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
| AR089568A1 (es) | Compuestos heterociclicos y sus metodos de usos | |
| AR091185A1 (es) | Derivados de 1,2,4-triazol | |
| EA201791816A1 (ru) | Ингибиторы kv1.3 и их применение в медицине | |
| AR112907A1 (es) | Pirazoles inhibidores de monoacilglicerol lipasa (magl) | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |